title: Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment.
abstract: Serum concentrations of interleukin-6 (IL-6), IL-6-soluble receptor (sIL-6R), IL-6 gp130-soluble receptor (sgp130), ligand of receptor activator of nuclear factor (NF)-kappaB (RANKL), and osteoprotegerin (OPG) were determined in 42 patients with polyostotic Paget's disease of bone (PDB) and acquired resistance to clodronate (M/F ratio 23:19; mean age 58.5 +/- 9.4 years) in acute phase of disease and after oral risedronate treatment (30 mg/day for 8 weeks). At baseline, pagetic patients showed higher levels of OPG, sIL-6R, and IL-6 with lower levels of sgp130 compared to 24 age- and sex-matched controls (respectively, 4.69 +/- 1.27 vs. 2.87 +/- 0.54 pmol/L; 40.89 +/- 8.61 vs. 30.98 +/- 4.24 ng/ml; 3.59 +/- 0.97 vs. 1.8 +/- 0.9 pg/ml; 327.34 +/- 43.41 vs. 411.7 +/- 79.5 ng/ml). Response to treatment is related to a significant increase of OPG levels in all patients (from 4.69 +/- 1.27 to 5.48 +/- 1.31 pmol/L). The disease remission, that is, total alkaline phosphatase (tALP) levels within the normal range after therapy, was associated with a simultaneous increase in OPG and sgp130 levels. In patients with tALP higher than the normal range after therapy, the OPG increase was associated with a parallel increase in RANKL levels. Our data suggest that serum levels of components of RANKL/OPG and IL-6 systems, before and after treatment, may be used to better define a therapeutical strategy in pagetic patients.
authors.affiliation: Department of Clinical and Experimental Medicine, Federico II University Medical School, Via S. Pansini, 5-80131 Naples, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mossetti
authors.forename: Domenico
authors.initials: D
authors.lastname: Rendina
authors.forename: Gianpaolo
authors.initials: G
authors.lastname: De Filippo
authors.forename: Roberto
authors.initials: R
authors.lastname: Viceconti
authors.forename: Gilda
authors.initials: G
authors.lastname: Di Domenico
authors.forename: Michele
authors.initials: M
authors.lastname: Cioffi
authors.forename: Loredana
authors.initials: L
authors.lastname: Postiglione
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Nunziata
mesh_terms: D000368:Aged; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000097:blood* / Q000188:drug therapy*; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000097:blood*; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood*; D000068296:Risedronic Acid
chemical_list: D006023:Glycoproteins; D015850:Interleukin-6; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human; D000068296:Risedronic Acid; D012968:Etidronic Acid